Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
biote Corp.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results |
| 06/08/2023 |
8-K
| Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Submission of Matters to a ...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Amendment No. 1 to Warrant Agreement, by and between the Company and Continental Stock Transfer & Trust Company",
"Biote Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants IRVING, TX - June 8, 2023 - Biote , a leading solutions provider in preventive healthcare through the delivery of personalized hormone therapy, today announced the expiration and results of its previously announced offer to each holder of its outstanding warrants, each whole warrant exercisable for one share of Class A Common Stock, par value $0.0001 per share , of the Company, at an exercise price of $11.50 per share , the opportunity to receive 0.23 shares of Common Stock in exchange for each Warrant tendered by the holder and exchanged pursuant to the offer , and solicitation of consents from holders of the Warrants to amend the Warrant Agreement, dated as of March 1, 2021 , by and bet..." |
|
| 06/07/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Underwriting Agreement, by and among the Company, Roth Capital Partners, LLC, as the underwriter, and the Selling Stockholder named therein",
"Underwriting Agreement, by and among the Company, Roth Capital Partners, LLC, as the underwriter, and the Selling Stockholder named therein" |
|
| 05/19/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/09/2023 |
8-K
| Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Biote Reports First Quarter 2023 Financial Results New Initiative Targets Long-term Growth Opportunity in Men's Health Company Launches Warrant Exchange Offer and Consent Solicitation Maintains 2023 Financial Guidance",
"Biote Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants IRVING, TX - May 9, 2023 - Biote , a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that it has commenced an exchange offer and consent solicitation relating to its 8,397,624 outstanding public warrants to purchase Class A common stock of the Company $0.0001 par value per share , which warrants trade on the Nasdaq Stock Market under the symbol “BTMDW” and 5,106,508 private placement warrants . The purpose of the Offer and Consent Solicitation is to simplify the Company's capital structure and reduce the potential dilutive impact of the warrants. Until the Expiration Date , we are offering to the holders of Warrants the oppo..." |
|
| 03/28/2023 |
8-K
| Quarterly results |
| 03/24/2023 |
8-K
| Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review  ... |
| 02/22/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/08/2022 |
8-K
| Quarterly results |
| 11/07/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/11/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Biote Releases Updated Corporate Presentation for October 2022 October 10, 2022 IRVING, Texas——Oct. 10, 2022—biote Corp. , a high growth, differentiated medical practice-building business within the hormone optimization space, today released a new Corporate Presentation, which the Company may use from time to time in communications with investors or potential investors. The updated presentation for October can be found under the Investor Relations section of biote's website at https://ir.biote.com/news-events/presentations. About Biote Biote is a woman-led company operating a high growth, differentiated medical practice-building business within the hormone optimization space. Similar to a franchise model, Biote provides the necessary components to enable practitioners to establish, build, ..." |
|
| 08/25/2022 |
8-K
| Quarterly results |
| 08/24/2022 |
8-K
| Quarterly results |
| 08/09/2022 |
8-K
| Quarterly results |
| 07/28/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ... |
| 07/19/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 07/19/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 06/09/2022 |
8-K
| Quarterly results |
| 06/02/2022 |
8-K
| Quarterly results |
| 05/26/2022 |
8-K
| Quarterly results |
| 05/24/2022 |
8-K
| Quarterly results |
| 05/11/2022 |
8-K
| Quarterly results |
| 03/30/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 03/04/2022 |
8-K
| Quarterly results |
| 12/13/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 12/13/2021 |
8-K
| Quarterly results |
| 11/18/2021 |
8-K
| Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review  ... |
| 05/17/2021 |
8-K
| Quarterly results |
| 04/19/2021 |
8-K
| Quarterly results |
| 03/10/2021 |
8-K
| Quarterly results |
| 03/05/2021 |
8-K
| Quarterly results |
|
|